AKT1 and B-cell chronic lymphocytic leukemia: Interestingly, the pattern of response to specific kinase inhibitors differed between RL and CLL cells as, in contrast to CLL cells, AKT pathway inhibitors completely reversed anti-IgM-induced PDCD4 downregulation and U0126 had no effect in RL cells.